Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients

Dupixent ® (dupilumab) s ignificantly i mproved i tch and h ives in p atients with c hronic s pontaneous u rticaria, a s tep f orward in d emonstrating the r ole of t ype 2 i nflammation in t hese p atients
REGN Ratings Summary
REGN Quant Ranking